Recently discovered adipokines and cardio-metabolic comorbidities in childhood obesity

International Journal of Molecular Sciences

Volumn 15, Issue 11, 2014, Pages 19760-19776

  Barraco, Gloria Maria ^a   Luciano, Rosa ^a   Semeraro, Michela ^a   Prieto Hontoria, Pedro L ^b   Manco, Melania ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b Facultad de Estudios del Patrimonio Cultural   (Chile)

Author keywords

Adipokines; Adipose tissue; Cardiovascular disease; Childhood obesity; Inflammation; Metabolic syndrome

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CHEMERIN; CYTOKERATIN 18; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FATTY ACID; FATTY ACID BINDING PROTEIN 4; FIBROBLAST GROWTH FACTOR 21; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; LEPTIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OMENTIN 1; UNCLASSIFIED DRUG; VASPIN; CHEMERIN PROTEIN, HUMAN; CHEMOKINE; FATTY ACID BINDING PROTEIN; FIBROBLAST GROWTH FACTOR; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; ITLN1 PROTEIN, HUMAN; LECTIN; SERINE PROTEINASE INHIBITOR; SERPINA12 PROTEIN, HUMAN; SIGNAL PEPTIDE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; BROWN ADIPOSE TISSUE; CARDIOMETABOLIC RISK; CHILDHOOD OBESITY; COMORBIDITY; HUMAN; HYPERPLASIA; INSULIN BLOOD LEVEL; INTRAABDOMINAL FAT; LIFESTYLE MODIFICATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; VITAMIN D DEFICIENCY; WAIST CIRCUMFERENCE; WEIGHT CHANGE; WHITE ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; COMPLICATION; METABOLIC DISORDER; METABOLISM; PATHOLOGY;

ADIPOKINES; ADIPOSE TISSUE, WHITE; CARDIOVASCULAR DISEASES; CHEMOKINES; CYTOKINES; FATTY ACID-BINDING PROTEINS; FIBROBLAST GROWTH FACTORS; GPI-LINKED PROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LECTINS; METABOLIC DISEASES; PEDIATRIC OBESITY; SERPINS;

EID: 84908329870     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms151119760     Document Type: Review

References (74)

1. Cali, A.M.; Caprio, S. Obesity in children and adolescents. J. Clin. Endocrinol. Metab. 2008, 93, S31-S36.
2. Spalding, K.L.; Arner, E.; Westermark, P.O.; Bernard, S.; Buchholz, B.A.; Bergmann, O.; Blomqvist, L.; Hoffstedt, J.; Näslund, E.; Britton, T., et al. Dynamics of fat cell turnover in humans. Nature 2008, 453, 783-787.
3. Virtanen, K.A.; Lidell, M.E.; Orava, J.; Heglind, M.; Westergren, R.; Niemi, T.; Taittonen, M.; Laine, J.; Savisto, N.-J.; Enerba ck, S., et al. Functional brown adipose tissue in healthy adults. N. Engl. J. Med. 2009, 360, 1518-1525.
4. Balagopal, P.B.; de Ferranti, S.D.; Cook, S.; Daniels, S.R.; Gidding, S.S.; Hayman, L.L.; McCrindle, B.W.; Mietus-Snyder, M.L.; Steinberger, J. Nontraditional risk factors and biomarkers for cardiovascular disease: Mechanistic, research, and clinical considerations for youth-A scientific statement from the American Heart Association. Circulation 2011, 123, 2749-2769.
5. Corripio, R.; Gonzalez-Clemente, J.M.; Perez-Sanchez, J.; Naf, S.; Gallart, L.; Nosas, R.; Vendrell, J.; Caixàs, A. Weight loss in prepubertal obese children is associated with a decrease in adipocyte fatty-acid-binding protein without changes in lipocalin-2: A 2-year longitudinal study. Eur. J. Endocrinol. 2010, 163, 887-893.
6. Choi, K.M.; Yannakoulia, M.; Park, M.S.; Cho, G.J.; Kim, J.H.; Lee, S.H.; Hwang, T.G.; Yang, S.J.; Kim, S.M.; Yoo, H.J., et al. Serum adipocyte fatty acid-binding protein, retinol-binding protein 4, and adiponectin concentrations in relation to the development of the metabolic syndrome in korean boys: A 3-year prospective cohort study. Am. J. Clin. Nutr. 2011, 93, 19-26.
7. Yun, K.E.; Kim, S.M.; Choi, K.M.; Park, H.S. Association between adipocyte fatty acid-binding protein levels and childhood obesity in korean children. Metabolism 2009, 58, 798-802.
8. Krzystek-Korpacka, M.; Patryn, E.; Bednarz-Misa, I.; Mierzchala, M.; Hotowy, K.; Czapinska, E.; Kustzeba-Wojcicka, I.; Gamian, A.; Noczynska, A. Circulating adipocyte fatty acid-binding protein, juvenile obesity, and metabolic syndrome. J. Pediatr. Endocrinol. Metable 2011, 24, 921-928.
9. Reinehr, T.; Stoffel-Wagner, B.; Roth, C.L. Adipocyte fatty acid-binding protein in obese children before and after weight loss. Metabolism 2007, 56, 1735-1741.
10. Schipper, H.S.; Nuboer, R.; Prop, S.; van den Ham, H.J.; de Boer, F.K.; Kesmir, C.; Mombers, I.M.; van Bekkum, K.A.; Woudstra, J.; Kieft, J.H., et al. Systemic inflammation in childhood obesity: Circulating inflammatory mediators and activated CD14++ monocytes. Diabetologia 2012, 55, 2800-2810.
11. Reyman, M.; Verrijn Stuart, A.A.; van Summeren, M.; Rakhshandehroo, M.; Nuboer, R.; de Boer, F.K.; van den Ham, H.J.; Kalkhoven, E.; Prakken, B.; Schipper, H.S. Vitamin D deficiency in childhood obesity is associated with high levels of circulating inflammatory mediators, and low insulin sensitivity. Int. J. Obes. (Lond.) 2014, 38, 46-52.
12. Landgraf, K.; Friebe, D.; Ullrich, T.; Kratzsch, J.; Dittrich, K.; Herberth, G.; Adams, V.; Kiess, W.; Erbs, S.; Korner, A. Chemerin as a mediator between obesity and vascular inflammation in children. J. Clin. Endocrinol. Metable 2012, 97, E556-E564.
13. Zhang, X.; Yeung, D.C.; Karpisek, M.; Stejskal, D.; Zhou, Z.G.; Liu, F.; Wong, R.L.; Chow, W.S.; Tso, A.W.; Lam, K.S.L., et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008, 5, 1246-1253.
14. Reinehr, T.; Woelfle, J.; Wunsch, R.; Roth, C.L. Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: A longitudinal analysis. J. Clin. Endocrinol. Metable 2012, 97, 2143-2150.
15. Akelma, A.Z.; Abaci, A.; Ozdemir, O.; Celik, A.; Avci, Z.; Razi, C.H.; Hizli, S.; Akin, O. The association of serum lipocalin-2 levels with metabolic and clinical parameters in obese children: A pilot study. J. Pediatr. Endocrinol. Metable 2012, 25, 525-528.
16. Kanaka-Gantenbein, C.; Margeli, A.; Pervanidou, P.; Sakka, S.; Mastorakos, G.; Chrousos, G.P.; Papassotiriou, I. Retinol-binding protein 4 and lipocalin-2 in childhood and adolescent obesity: When children are not just “small adults”. Clin. Chem. 2008, 54, 1176-1182.
17. Catli, G.; Anik, A.; Abaci, A.; Kume, T.; Bober, E. Low omentin-1 levels are related with clinical and metabolic parameters in obese children. Exp. Clin. Endocrinol. Diabetes 2013, 121, 595-600.
18. Ko, B.J.; Lee, M.; Park, H.S.; Han, K.; Cho, G.J.; Hwang, T.G.; Kim, J.H.; Lee, S.H.; Lee, H.Y.; Kim, S.M. Elevated vaspin and leptin levels are associated with obesity in prepubertal Korean children. Endocr. J. 2013, 60, 609-616.
19. Suleymanoglu, S.; Tascilar, E.; Pirgon, O.; Tapan, S.; Meral, C.; Abaci, A. Vaspin and its correlation with insulin sensitivity indices in obese children. Diabetes Res. Clin. Pract. 2009, 84, 325-328.
20. Korner, A.; Neef, M.; Friebe, D.; Erbs, S.; Kratzsch, J.; Dittrich, K.; Bluher, S.; kapellen, T.M.; Kovacs, P.; Stumvoll, M., et al. Vaspin is related to gender, puberty and deteriorating insulin sensitivity in children. Int. J. Obes. (Lond.) 2011, 35, 578-586.
21. Martos-Moreno, G.A.; Kratzsch, J.; Korner, A.; Barrios, V.; Hawkins, F.; Kiess, W.; Argente, J. Serum visfatin and vaspin levels in prepubertal children: Effect of obesity and weight loss after behavior modifications on their secretion and relationship with glucose metabolism. Int. J. Obes. (Lond.) 2011, 35, 1355-1362.
22. Martos-Moreno, G.A.; Barrios, V.; Chowen, J.A.; Argente, J. Adipokines in childhood obesity. Vitam. Horm. 2013, 91, 107-142.
23. Manco, M.; Putignani, L.; Bottazzo, G.F. Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr. Rev. 2010, 31, 817-844.
24. Taveras, E.M.; Rifas-Shiman, S.L.; Belfort, M.B.; Kleinman, K.P.; Oken, E.; Gillman, M.W. Weight status in the first 6 months of life and obesity at 3 years of age. Pediatrics 2009, 123, 1177-1183.
25. Rolland-Cachera, M.F.; Deheeger, M.; Bellisle, F.; Sempé, M.; Guilloud-Bataille, M.; Patois, E. Adiposity rebound in children: a simple indicator for predicting obesity. Am. J. Clin. Nutr. 1984, 39, 129-135.
26. Cannon, B.; Nedergaard, J. Brown adipose tissue: function and physiological significance. Physiol. Rev. 2004, 84, 277-359.
27. Drubach, L.A.; Palmer, E.L., Connolly, L.P.; Baker, A.; Zurakowski, D.; Cypess, A.M. Pediatric brown adipose tissue: detection, epidemiology, and differences from adults. J. Pediatr. 2011, 159, 939-944.
28. Villarroya, J.; Cereijo, R.; Villarroya, F. An endocrine role for brown adipose tissue? Am. J. Physiol. Endocrinol. Metable 2013, 305, E567-E572.
29. Daniels, S.R.; Arnett, D.K.; Eckel, R.H.; Gidding, S.S.; Hayman, L.L.; Kumanyika, S.; Robinson, T.N.; Scott, B.J.; St Jeor, S.; Williams, C.L. Overweight in children and adolescents. Pathophysiology, consequences, prevention, and treatment. Circulation 2005, 111, 1999-2012.
30. Taksali, S.E.; Caprio, S.; Dziura, J.; Dufour, S.; Cali, A.M.; Goodman, T.R.; Papademetris, X.; Burgert, T.S.; Pierpont, B.M.; Savoye, A.A., et al. High visceral and low abdominal subcutaneous fat stores in the obese adolescent: A determinant of an adverse metabolic phenotype. Diabetes 2008, 57, 367-371.
31. Manco, M.; Bottazzo, G.; DeVito, R.; Marcellini, M.; Mingrone, G.; Nobili, V. Nonalcoholic fatty liver disease in children. J. Am. Coll. Nutr. 2008, 27, 667-676.
32. Manco, M.; Morandi, A.; Marigliano, M.; Rigotti, F.; Manfredi, R.; Maffeis, C. Epicardial fat, abdominal adiposity and insulin resistance in obese pre-pubertal and early pubertal children. Atherosclerosis 2013, 226, 490-495.
33. Furuhashi, M.; Fucho, R.; Gorgun, C.Z.; Tuncman, G.; Cao, H.; Hotamisligil, G.S. Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J. Clin. Investig. 2008, 118, 2640-2650.
34. Rolph, M.S.; Young, T.R.; Shum, B.O.; Gorgun, C.Z.; Schmitz-Peiffer, C.; Ramshaw, I.A.; Hotamisligil, G.S.; Mackay, C.R. Regulation of dendritic cell function and T cell priming by the fatty acid-binding protein AP2. J. Immunol. 2006, 177, 7794-7801.
35. Xu, A.; Wang, Y.; Xu, J.Y.; Stejskal, D.; Tam, S.; Zhang, J.; Wat, N.M.; Wong, W.K.; Lam, K.S. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin. Chem. 2006, 52, 405-413.
36. Cabre, A.; Lazaro, I.; Girona, J.; Manzanares, J.M.; Marimon, F.; Plana, N.; Heras, M.; Masana, L. Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis 2007, 195, e150-e158.
37. Milner, K.L.; van der Poorten, D.; Xu, A.; Bugianesi, E.; Kench, J.G.; Lam, K.S.; Chisholm, D.J.; George, J. Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology 2009, 49, 1926-1934.
38. Kralisch, S.; Fasshauer, M. Adipocyte fatty acid binding protein: A novel adipokine involved in the pathogenesis of metabolic and vascular disease? Diabetologia 2013, 56, 10-21.
39. Wittamer, V.; Franssen, J.D.; Vulcano, M.; Mirjolet, J.F.; le Poul, E.; Migeotte, I.; Brèzillon, S.; Tyldesley, R.; Blanpain, C.; Detheux, M., et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J. Exp. Med. 2003, 198, 977-985.
40. Goralski, K.B.; McCarthy, T.C.; Hanniman, E.A.; Zabel, B.A.; Butcher, E.C.; Parlee, S.D.; Muruganandan, S.; Sinal, C.J. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J. Biol. Chem. 2007, 282, 28175-28141.
41. Shin, H.Y.; Lee, D.C.; Chu, S.H.; Jeon, J.Y.; Lee, M.K.; Im, J.A.; Lee, J.W. Chemerin levels are positively correlated with abdominal visceral fat accumulation. Clin. Endocrinol. (Oxf.) 2012, 77, 47-50.
42. Chu, S.H.; Lee, M.K.; Ahn, K.Y.; Im, J.A.; Park, M.S.; Lee, D.C.; Jeon, J.Y.; Lee, J.W. Chemerin and adiponectin contribute reciprocally to metabolic syndrome. PLoS One 2012, 7, e34710.
43. Takahashi, M.; Takahashi, Y.; Takahashi, K.; Zolotaryov, F.N.; Hong, K.S.; Kitazawa, R.; Lida, K.; Okimura, Y.; Kaji, H.; Kitazawa, S., et al. Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. FEBS Lett. 2008, 582, 573-578.
44. Rourke, J.L.; Dranse, H.J.; Sinal, C.J. Towards an integrative approach to understanding the role of chemerin in human health and disease. Obes. Rev. 2013, 14, 245-262.
45. Yamawaki, H.; Kameshima, S.; Usui, T.; Okada, M.; Hara, Y. A novel adipocytokine, chemerin exerts anti-inflammatory roles in human vascular endothelial cells. Biochem. Biophys. Res. Commun. 2012, 423, 152-157.
46. Kharitonenkov, A. FGFs and metabolism. Curr. Opin. Pharmacol. 2009, 9, 805-810.
47. Nishimura, T.; Nakatake, Y.; Konishi, M.; Itoh, N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim. Biophys. Acta 2000, 1492, 203-206.
48. Hondares, E.; Gallego-Escuredo, J.M.; Flachs, P.; Frontini, A.; Cereijo, R.; Goday, A.; Perugini, J.; Kopecky, P.; Giralt, M.; Cinti, S., et al. Fibroblast growth factor-21 is expressed in neonatal and pheochromocytoma-induced adult human brown adipose tissue. Metabolism 2014, 63, 312-317.
49. Berglund, E.D.; Li, C.Y.; Bina, H.A.; Lynes, S.E.; Michael, M.D.; Shanafelt, A.B.; Kharitonenkov, A.; Wasserman, D.H. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 2009, 150, 4084-4093.
50. Kharitonenkov, A.; Shiyanova, T.L.; Koester, A.; Ford, A.M.; Micanovic, R.; Galbreath, E.J.; Sandusky, G.E.; Hammond, L.J.; Moyers, J.S.; Owens, R.A., et al. FGF-21 as a novel metabolic regulator. J. Clin. Investig. 2005, 115, 1627-1635.
51. Kharitonenkov, A.; Wroblewski, V.J.; Koester, A.; Chen, Y.F.; Clutinger, C.K.; Tigno, X.T.; Hansen, B.C.; Shanafelt, A.B.; Etgen, G.J. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007, 148, 774-781.
52. Coskun, T.; Bina, H.A.; Schneider, M.A.; Dunbar, J.D.; Hu, C.C.; Chen, Y.; Moller, D.E.; Kharitonenkow, A. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008, 149, 6018-6027.
53. Fisher, F.M.; Kleiner, S.; Douris, N.; Fox, E.C.; Mepani, R.J.; Verdeguer, F.; Wu, J.; Kharitonenkov, A.; Flier, J.S.; Maratos-Flier, E., et al. FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis. Genes Dev. 2012, 26, 271-281.
54. Iglesias, P.; Selgas, R.; Romero, S.; Diez, J.J. Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21. Eur. J. Endocrinol. 2012, 167, 301-309.
55. Dushay, J.; Chui, P.C.; Gopalakrishnan, G.S.; Varela-Rey, M.; Crawley, M.; Fisher, F.M.; Badman, M.K.; Martinez-Chantar, M.L.; Maratos-Flier, E. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010, 139, 456-463.
56. Giannini, C.; Feldstein, A.E.; Santoro, N.; Kim, G.; Kursawe, R.; Pierpont, B.; Caprio, S. Circulating levels of FGF-21 in obese youth: Associations with liver fat content and markers of liver damage. J. Clin. Endocrinol. Metable 2013, 98, 2993-3000.
57. Feldstein, A.E.; Alkhouri, N.; de Vito, R.; Alisi, A.; Lopez, R.; Nobili, V. Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children. Am. J. Gastroenterol. 2013, 108, 1526-1531.
58. Mai, K.; Andres, J.; Biedasek, K.; Weicht, J.; Bobbert, T.; Sabath, M.; Meinus, S.; Reinecke, F.; Mohlig, M.; Weickert, M.O.; et al. Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21. Diabetes 2009, 58, 1532-1538.
59. Kjeldsen, L.; Johnsen, A.H.; Sengelov, H.; Borregaard, N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J. Biol. Chem. 1993, 268, 10425-10432.
60. Auguet, T.; Quintero, Y.; Terra, X.; Martinez, S.; Lucas, A.; Pellitero, S.; Aguilar, C.; Hernandez, M.; del Castillo, D.; Richart, C. Upregulation of lipocalin 2 in adipose tissues of severely obese women: Positive relationship with proinflammatory cytokines. Obesity 2011, 19, 2295-2300.
61. Wang, Y.; Lam, K.S.; Kraegen, E.W.; Sweeney, G.; Zhang, J.; Tso, A.W.; Chow, W.S.; Wat, N.M.; Xu, J.Y.; Hoo, R.L., et al. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin. Chem. 2007, 53, 34-41.
62. Liu, X.; Hamnvik, O.P.; Petrou, M.; Gong, H.; Chamberland, J.P.; Christophi, C.A.; Kales, S.N.; Christiani, D.C.; Mantzoros, C.S. Circulating lipocalin 2 is associated with body fat distribution at baseline but is not an independent predictor of insulin resistance: The prospective cyprus metabolism study. Eur. J. Endocrinol. 2011, 165, 805-812.
63. Tsuji, S.; Uehori, J.; Matsumoto, M.; Suzuki, Y.; Matsuhisa, A.; Toyoshima, K.; Seya, T. Human intelectin is a novel soluble lectin that recognizes galactofuranose in carbohydrate chains of bacterial cell wall. J. Biol. Chem. 2001, 276, 23456-23463.
64. Yang, R.Z.; Lee, M.J.; Hu, H.; Pray, J.; Wu, H.B.; Hansen, B.C.; Shuldiner, A.R.; Fried, S.K.; `Lenithan, J.C.; Gong, D.W. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: Possible role in modulating insulin action. Am. J. Physiol. Endocrinol. Metable 2006, 290, E1253-E1261.
65. Jaikanth, C.; Gurumurthy, P.; Cherian, K.M.; Indhumathi, T. Emergence of omentin as a pleiotropic adipocytokine. Exp. Clin. Endocrinol. Diabetes 2013, 121, 377-383.
66. De Souza Batista, C.M.; Yang, R.Z.; Lee, M.J.; Glynn, N.M.; Yu, D.Z.; Pray, J.; Ndubuizu, K.; Patil, S.; Schwartz, A. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007, 56, 1655-1661.
67. Prats-Puig, A.; Bassols, J.; Bargallo, E.; Mas-Parareda, M.; Ribot, R.; Soriano-Rodriguez, P.; Berebgui, A.; Diaz, M.; de Zegher, F.; Ibanez, L., et al. Toward an early marker of metabolic dysfunction: Omentin-1 in prepubertal children. Obesity 2011, 19, 1905-1907.
68. Kloting, N.; Kovacs, P.; Kern, M.; Heiker, J.T.; Fasshauer, M.; Schon, M.R.; Stumvoll, M.; Beck-Sickinger, A.G.; Bluher, M. Central vaspin administration acutely reduces food intake and has sustained blood glucose-lowering effects. Diabetologia 2011, 54, 1819-1823.
69. Hida, K.; Wada, J.; Eguchi, J.; Zhang, H.; Baba, M.; Seida, A.; Hashimoto, I.; Okada, T.; Yasuhara, A.; Nakatsuka, A., et al. Visceral adipose tissue-derived serine protease inhibitor: A unique insulin-sensitizing adipocytokine in obesity. Proc. Natl. Acad. Sci. USA 2005, 102, 10610-10615.
70. Bluher, M. Vaspin in obesity and diabetes: Pathophysiological and clinical significance. Endocrine 2012, 41, 176-182.
71. Youn, B.S.; Kloting, N.; Kratzsch, J.; Lee, N.; Park, J.W.; Song, E.S.; Ruschke, K.; Oberbach, A.; Fasshauer, M.; Stumvoll, M., et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008, 57, 372-377.
72. Kloting, N.; Berndt, J.; Kralisch, S.; Kovacs, P.; Fasshauer, M.; Schon, M.R.; Stumvoll, M.; Blüher, M. Vaspin gene expression in human adipose tissue: Association with obesity and type 2 diabetes. Biochem. Biophys. Res. Commun. 2006, 339, 430-436.
73. Lee, M.K.; Jekal, Y.; Im, J.A.; Kim, E.; Lee, S.H.; Park, J.H.; Chu, S.H.; Chung, K.M.; Lee, H.C.; Oh, E.G., et al. Reduced serum vaspin concentrations in obese children following short-term intensive lifestyle modification. Clin. Chim. Acta 2010, 411, 381-385.
74. Spiroglou, S.G.; Kostopoulos, C.G.; Varakis, J.N.; Papadaki, H.H. Adipokines in periaortic and epicardial adipose tissue: Differential expression and relation to atherosclerosis. J. Atheroscler. Thromb. 2010, 17, 115-130.